Sign in
Enrolling by invitationPhase 2

Tests lurbinectedin in people with high-grade pancreatic neuroendocrine tumors

Tests lurbinectedin as a later treatment for high-grade pancreatic neuroendocrine tumors.

Key facts

Who runs it
National Cancer Center, Korea
Where
Goyang-si, South KoreaSee the site
Trial code
Registry title
Patients With High-grade Pancreatic Neuroendocrine Tumors
Status
Enrolling by invitation
Phase
Phase 2
People taking part
46 people, planned
Started
23 Sept 2025
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Lurbinectedin 4 MG Injection [Zepzelca]
Record updated
1 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a pancreatic neuroendocrine tumor or carcinoma whose earlier standard cancer treatment did not work. It tests lurbinectedin as second-line treatment.

Age
19 years or older
Sex
All sexes can join.
Disease stage
Pancreatic neuroendocrine tumor or neuroendocrine carcinoma (high-grade).
Earlier treatment
Earlier standard anti-cancer treatment must have failed.

Main reasons for not taking part

  • Being treated for another cancer (unless treatment ended and no disease for at least 2 years)
  • Pregnant or breastfeeding women
  • The investigator judges the person unsuitable for medical reasons

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Clinical diagnosis of Pancreatic neuroendocrine tumor or neuroendocrine carcinoma
  • Documented failure of prior standard anti-cancer treatment
  • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³
  • Platelet count ≥ 100,000 cells/mm³
  • Ability to understand study content, willingness to comply with study procedures, and commitment to complete the study

Who cannot take part

  • Currently receiving treatment for other cancers (except those who completed treatment and have been disease-free for at least 2 years prior to enrollment)
  • Pregnant or breastfeeding women
  • Deemed unsuitable for participation by the investigator due to clinical or medical reasons

Where in South Korea

  • National Cancer CenterGoyang-si, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 pNETs or pNECs. * Cisplatin/etoposide remains the treatment of choice for high-grade pNET/pNEC. Other irinotecan-based therapies, such as FOLFIRI (cisplatin/irinotecan), FOLFOX, and temozolomide ± capecitabine, have been employed; however, a standard of care remains to be established.

The group in the trial

  • single armTreatment being tested

    Lurbinectedin shall be administered intravenously at a dose of 3.2 mg/m2 over 60 minutes every 21 days. The administration of the study drug shall be continued until disease progression or the occurrence of unacceptable toxicity.

    Treatment: Lurbinectedin 4 MG Injection [Zepzelca]

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Lurbinectedin as a Second-line Treatment for High-grade Pancreatic Neuroendocrine Tumors
Plain-language title
Tests lurbinectedin in people with high-grade pancreatic neuroendocrine tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
1 October 2025